Ondansetron for Bipolarity and Alcohol Use Disorders
This study is completed. It focuses on bipolarity and currently lists study information in the United States.
In Dallas
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This study is completed. It focuses on bipolarity and currently lists study information in the United States.
In DallasThis study has public registry information. It focuses on bipolarity and currently lists study information in Canada.
Multiple locations, including CalgaryThis study is completed. It focuses on bipolarity and currently lists study information in the United States.
In BostonThis study is completed. It focuses on bipolarity and currently lists study information in Austria, Canada, Colombia, Czech Republic, Germany, Guatemala, Peru, Russian Federation, Slovakia, South Africa, Ukraine, the United States, and Venezuela.
Multiple locations, including La PalmaThis study is enrolling by invitation. It focuses on schizophrenia and currently lists participation information in the United States.
In BelmontThis study was terminated in Global. It is testing Open-label Adjunctive Zonisamide for Bipolarity.
In GlobalThis study was withdrawn in the United States. It focuses on depression.
In GalvestonThis study is completed in the United States. It is testing pharmacokinetics of Aripiprazole for schizophrenia.
Multiple locations, including Garden GroveThis study was withdrawn in the United States. It is testing latuda for Bipolarity.
In BostonThis study is completed in the United States. It is testing N-Acetylcysteine for Bipolarity.
In BostonThis study is completed in the United States, in France, in Canada, .... It is testing intramuscular Formulation of Aripiprazole for Bipolarity.
Multiple locations, including BirminghamThis study is completed in the United States. It focuses on Schizophrenia.
In New YorkHopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.